Navigation Links
Bioheart Announces Plans to Advance LVAD + Muscle Stem Cells Clinical Trial
Date:12/8/2010

nfarctions and lower limb ischemia utilizing adipose (fat) derived cells.  Bioheart is focused on heart failure and has a building pipeline of product developments to assist care providers in treating and caring for these patients.

Forward-Looking Statements:Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) our ability to control and reduce our expenses; (iii) our ability to establish a distribution network for and commence distribution of certain products for which we have acquired distribution rights; (iv) our ability to timely and successfully complete our clinical trials; (v) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (vi) the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; (vii) our dependence on the success of our lead product candidate; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; (ix) our ability to protect our intellectual property rights; and (x) intense competition. The Company is also subject to the risks and uncertainties described in its filings with the Securities an
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
2. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
3. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
4. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
5. Leading Experts Endorse Biohearts Muscle Stem Cell MyoCell Therapy
6. Biohearts MyoCell Recognized as one of the Breakthrough Developments of 2010
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014  Decision Resources Group finds ... eligible for biologic therapy, only a proportion ... gastroenterologists cite patients, discomfort with biological therapy ... rates, followed by cost-related issues and payer ... biologics, Janssen Biotech,s Remicade and AbbVie,s Humira ...
(Date:9/17/2014)... -- Bronstein, Gewirtz & Grossman, LLC is investigating potential ... PDL BioPharma, Inc. ("PDL BioPharma" or the "Company") (NasdaqGS: ... to contact Peretz Bronstein or his investor ... or 212-697-6484. The investigation focuses on ... federal securities laws. On September 16, 2014, ...
(Date:9/17/2014)... PRAIRIE, Minn. , Sept. 17, 2014 ... and global market leader of advanced imaging modalities for ... Ultrasound System in two live cases at the Transcatheter ... The cases were presented from Medstar Washington Hospital ... York-Presbyterian Hospital/Columbia University Medical Center ( New York, ...
Breaking Medicine Technology:The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2ACIST Launches HDi High-Definition IVUS 2ACIST Launches HDi High-Definition IVUS 3
... , JERUSALEM , Jan. ... company, announced today that it has granted Novartis an option to ... Permeability Enhancer (TPE) technology for use with certain related small molecule ... a separate but related agreement, the MPM Bio IV NVS Strategic ...
... , FRANKLIN LAKES, N.J. , Jan. 19 ... scheduled to present at the following investor conferences: , Brian Griffin ... Global Healthcare Services Conference on Monday, January 25, 2010 at ... New York ; , David B. Snow Jr. , Medco chairman ...
Cached Medicine Technology:Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products 2Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products 3Medco to Present at Upcoming Investor Conferences 2
(Date:9/17/2014)... 17, 2014 As kinship care continues ... who cannot live with their parents, emphasis on kinship ... to enhance services and supports for kinship caregivers and ... National Kinship Care Conference is being held this week ... best practice, policy, program and service development for kinship ...
(Date:9/17/2014)... Final Cut Pro X plugin developers have ... Pixel Film Studios. , “ProBlue 5k is a compilation of ... to epic,” said Christina Austin, CEO of Pixel Film Studios. ... a definite game changer.” , ProBlue 5k is the ultimate ... filmmaker ! This footage compilation of over 100 anamorphic flares ...
(Date:9/17/2014)... first-of-its-kind research study was announced today that will ... impact long-term wellness and contribute to healthy aging. ... Center and funded through a $10 million unrestricted ... Fund, WELL aims to identify lifestyle and environmental ... and wellness as they age. WELL will be ...
(Date:9/17/2014)... September 17, 2014 In its latest blog ... and believes that having family close by during a stay ... not the process is successful, is highlighting a member of ... in the lives of addicts across the country and around ... therapy can reduce the blood pressure, heart rate, and stress ...
(Date:9/17/2014)... these sound like the ideas of a ... components of an exciting new approach to imaging ... of metastatic prostate cancer, scientists at Virginia Commonwealth ... Medicine and Johns Hopkins Medical Institutions have provided ... could revolutionize doctors, ability to see tumors that ...
Breaking Medicine News(10 mins):Health News:Arizona’s Children Association Kinship Service Providers Invited to Present at the CWLA National Conference 2Health News:A New Plugin Entitled ProBlue 5k Was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:First-ever research study examines impacts of diet and lifestyle on healthy aging 2Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3
... of Economy, Vet Difficulties Demonstrate Urgency; Advances in ... Mental Health America, the country,s oldest and ... mentally healthier lives, today called for action on ... for Mental Health."To view the Multimedia News Release, ...
... Customers; Reaches 400,000 Live User Milestone; Named #1 SSO ... identity and access management (IAM) solutions are the most ... the best performance in the Company,s history. In ... new user licenses. In addition, the Company reached ...
... at the University of Texas Medical Branch at Galveston ... fever virus uses to disarm the defenses of infected ... in humans, inflicting liver damage, blindness and even death ... Rift Valley fever also afflicts cattle, goats and sheep, ...
... N.M., Feb. 17 Exagen Diagnostics, Inc., which ... for research and analytic specific reagents to clinical ... Alsobrook, Ph.D., has been named vice president and ... oversees Exagen,s day-to-day operations, company alliances and genomic ...
... Effect on Executive Function and Functional Capacity are ... According to a New Report from Decision ResourcesWALTHAM, ... the world,s leading research and advisory firms for ... drug were to receive formal regulatory approval for ...
... procedure rooms offer faster and more accurate diagnosis and ... Medical Center today announces the completion of its state-of-the-art ... Now located on the second level of the ... with three fully functional state-of-the-art catheterization labs (cath labs) ...
Cached Medicine News:Health News:Video: On 100th Anniversary, Mental Health America Declares 'It's Time for Mental Health' 2Health News:Video: On 100th Anniversary, Mental Health America Declares 'It's Time for Mental Health' 3Health News:Video: On 100th Anniversary, Mental Health America Declares 'It's Time for Mental Health' 4Health News:Sentillion Announces 2008 as the Best Year in the Company's History 2Health News:Sentillion Announces 2008 as the Best Year in the Company's History 3Health News:Scientists uncover secrets of potential bioterror virus 2Health News:Exagen Diagnostics Names John Alsobrook, Ph.D., Vice President and Chief Operating Officer 2Health News:A Drug That Receives Regulatory Approval for Cognitive Impairment Associated With Schizophrenia Would Earn a Higher Patient Share in the United States Than in Europe 2Health News:A Drug That Receives Regulatory Approval for Cognitive Impairment Associated With Schizophrenia Would Earn a Higher Patient Share in the United States Than in Europe 3Health News:St. Mary Medical Center Opens New Cardiovascular Catheterization Labs Reaffirming Role as a Regional Leader in Cardiovascular Medicine 2Health News:St. Mary Medical Center Opens New Cardiovascular Catheterization Labs Reaffirming Role as a Regional Leader in Cardiovascular Medicine 3Health News:St. Mary Medical Center Opens New Cardiovascular Catheterization Labs Reaffirming Role as a Regional Leader in Cardiovascular Medicine 4Health News:St. Mary Medical Center Opens New Cardiovascular Catheterization Labs Reaffirming Role as a Regional Leader in Cardiovascular Medicine 5
... key clinical and economic issues of cerclage ... designed to maximize tension control while minimizing ... combines efficient instrumentation with a simple technique. ... is indicated for general orthopaedic trauma surgery ...
OmniAccess&trade Hip Retractor System sets a new standard in hip exposure. It provides constant, absolute exposure of the acetabulum during total hip arthroplasty and revision procedures....
... Many of DePuy's aggressive innovations have become ... to be equalled. The AML Total ... to efficiently address and effectively meet the ... arthroplasty. With greater than 15 years ...
The Endotrac™ System includes an Obturator, Slotted Cannula, Synovial Elevator, Ligament Probe, Ligament Rasp, Blade Handle, two Retractors and sterilizable tray. The Endotrac&trade....
Medicine Products: